Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma
about
Safety and efficacy of brentuximab vedotin in patients with Hodgkin lymphoma or systemic anaplastic large cell lymphomaHaploidentical Stem Cell Transplantation in Adult Haematological MalignanciesClinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated ReviewComparable Outcomes for Hematologic Malignancies after HLA-Haploidentical Transplantation with Posttransplantation Cyclophosphamide and HLA-Matched TransplantationModern approaches to HLA-haploidentical blood or marrow transplantationThe role of autologous and allogeneic hematopoietic stem cell transplantation for Hodgkin lymphomaPost-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantationAdvances in predicting acute GVHDOutcomes of haploidentical transplant compared with matched donor allogeneic stem cell transplant.Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantationIdiopathic Pneumonia Syndrome and Thrombotic Microangiopathy Following Nonmyeloablative Haploidentical Peripheral Blood Stem Cell Transplantation and Posttransplant Cyclophosphamide: A Case ReportAllogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome.Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphomaGraft-versus-Leukemia Effect Following Hematopoietic Stem Cell Transplantation for Leukemia.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesHigh-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantationNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell TrAllogeneic hematopoietic cell transplantation: the state of the artMismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignanciesThe Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphomaNonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcomeT-cell-replete haploidentical HSCT with low-dose anti-T-lymphocyte globulin compared with matched sibling HSCT and unrelated HSCTDurable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.Histology and time to progression predict survival for lymphoma recurring after reduced-intensity conditioning and allogeneic hematopoietic cell transplantation.Treatment strategies for Hodgkin lymphoma recurring following autologous hematopoietic stem cell transplantation.Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning.Three-dimensional structure discrepancy between HLA alleles for effective prediction of aGVHD severity and optimal selection of recipient-donor pairs: a proof-of-concept studyMight haplo "be the (better) match"?Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide.Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance.Natural killer cell-enriched donor lymphocyte infusions from A 3-6/6 HLA matched family member following nonmyeloablative allogeneic stem cell transplantation.Haploidentical Transplantation Without In Vitro T-Cell Depletion Results in Outcomes Equivalent to Those of Contemporaneous Matched Sibling and Unrelated Donor Transplantation for Acute LeukemiaImpact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphomaAllogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis.Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin.HLA-haploidentical stem cell transplantation for hematologic malignancies.
P2860
Q24633761-B74D2801-E0F0-40D7-AABA-F03C1388C960Q26745527-8587372A-F12D-4F17-9FF4-F4B589340912Q26770716-F662594C-B7E5-49FF-9921-F05EE43F7EF3Q26771749-9B9930D9-413E-46E6-8D70-FE820E1D7C6CQ26797506-44755780-FD93-4634-B273-FF88B82F7067Q26822480-4929E11E-F5C1-48C7-AB88-D53750A95650Q26852474-33870915-CAFF-478F-9577-BDAF73D2D405Q27021123-345BA886-E4C4-489C-8E27-A83B364A0C8AQ30240140-16066EED-D5CF-4FA2-8DEC-D94D7AB9465BQ33400803-F79BD385-3D8F-40D3-9E15-D12FE4852AFAQ33424660-023BD3F5-5AD1-468D-89EC-A8FABB84C681Q33560410-FB374553-51A3-4930-893A-F249FE3D86EBQ33608520-96333F65-5947-4E18-B03F-A3372C9C0FCFQ33770125-775D0E2B-1707-4C6A-BBDA-59CBD1646ED2Q33886267-BC29CAAF-84B4-4DCA-87B2-39C4B36377FFQ33941128-B97815C9-D09C-4DA0-9BC4-61E43481D31DQ34044024-BB6E0DA9-F425-48BB-A277-19A985661FD0Q34145155-4C1B413C-DBFA-4333-9D64-92A4740EC592Q34175568-0F1A49C5-2A1D-433A-A820-A818A22081C8Q34240314-28708B20-66D6-4F32-AAB2-C3722901E1C1Q34325201-17FD828C-2461-4184-8B8E-F118408BBE3DQ34388640-08805429-8345-45D1-AFCF-581BB911F65FQ34398411-FF30CA21-AC4A-46FD-AB3B-A959B49AA2ACQ35103536-2D83EA2A-DC44-4387-B7D5-E8E420138A08Q35129248-3ACBC820-1AEF-42C5-8595-DDF481E90E56Q35223780-CE363655-10AA-446C-8442-09F4DC3A9E94Q35865599-A88F77DD-F45E-4B5C-A290-0CCF74351B5CQ36264895-4761033F-D52A-4592-8AF7-B1CBB3225E51Q36426327-BE7842A0-38BD-49AB-A4D5-69F9C170DACCQ36545617-97A40EEE-CADD-43A3-925A-6CF9C3DC42ABQ36596844-087EF357-E7A5-4E1E-8186-EA900060690CQ36724916-2F868ED9-615D-4AF5-A904-8380047A93A7Q36752218-231AEFA3-95D6-4856-896D-25BD105BA42BQ36763653-C4A80517-355D-44CF-AE71-0C9198567243Q36822659-E4ADB418-9BAC-4357-9B73-AE07C395C3A7Q37144910-30BC4D7F-38EF-4480-9A0C-D5FC69C91CD4Q37279128-ED5EEFA0-A43C-41C7-A14C-E1372C3F6A36Q37388718-4DB26469-968E-4D49-A7BB-66662DC82910Q37412853-478C8E06-6B1F-4643-A9B0-B0220F820825Q37627991-164226CA-60FA-49C8-9732-BE4157470070
P2860
Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Comparison of outcomes of HLA- ...... or refractory Hodgkin lymphoma
@en
Comparison of outcomes of HLA- ...... r refractory Hodgkin lymphoma.
@nl
type
label
Comparison of outcomes of HLA- ...... or refractory Hodgkin lymphoma
@en
Comparison of outcomes of HLA- ...... r refractory Hodgkin lymphoma.
@nl
prefLabel
Comparison of outcomes of HLA- ...... or refractory Hodgkin lymphoma
@en
Comparison of outcomes of HLA- ...... r refractory Hodgkin lymphoma.
@nl
P2093
P2860
P50
P1476
Comparison of outcomes of HLA- ...... or refractory Hodgkin lymphoma
@en
P2093
Benedetto Bruno
Dietger W Niederwieser
Ephraim J Fuchs
Finn B Petersen
Heather J Symons
Karl G Blume
Lauri M Burroughs
Leo Luznik
Michael A Pulsipher
Michael B Maris
P2860
P304
P356
10.1016/J.BBMT.2008.08.014
P577
2008-11-01T00:00:00Z